# Madhavan Balachandran

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/madhavan-balachandran
Canonical HTML page: https://getbiobrief.com/entity/madhavan-balachandran

## Timeline

- **2026-06-12**: SEC filings and market close — Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
- **2026-06-11**: Insider sales executed — Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
- **2026-05-05**: Q1 2026 earnings — uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
- **2026-03-09**: RBC upgrade — RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.

## Recent coverage (1 stories)

### 3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57
2026-08-05 19:24:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Full story: https://getbiobrief.com/story/uniqure-insider-sales-3-directors-sell-1993-shares-27-57

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.